# A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control

> **NCT07711288** · NA · NOT_YET_RECRUITING · sponsor: **Lembas** · enrollment: 35 (estimated)

## Conditions studied

- Postprandial Glycemic Control
- Prediabetic Overweight and Obese Adults

## Interventions

- **DIETARY_SUPPLEMENT:** Low dose alpha-galactosidase-derived peptide
- **DIETARY_SUPPLEMENT:** Medium dose alpha-galactosidase-derived peptide
- **DIETARY_SUPPLEMENT:** High dose alpha-galactosidase-derived peptide
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT07711288
- **Lead sponsor:** Lembas
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711288, "A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07711288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*